Sara Anvari, MD, AAAAI: Urticaria and/or Angioedema Events Secondary to mRNA Covid-19 Vaccinations -Updates from a National Case Registry

It was a pleasure to speak with Dr Sara Anvari (Baylor College of Medicine, Texas Children’s Hospital, TX, USA) about her presentation on the COVID-19 Vaccine Allergy Case Registry, where potential cases of severe hypersensitivity reactions to COVID-19 vaccines were collected. 

The abstract entitled ‘Urticaria and/or angioedema events secondary to mRNA COVID-19 vaccinations -Updates from a national case registry’ (Abstract #L05) was presented at The American Academy of Allergy, Asthma & Immunology (AAAAI), February 25-28, 2022

Questions:

1. Could you tell us a little about the COVID-19 Vaccine Allergy Case Registry and its aims? (00:22)
2. What were the findings of the registry study in terms of incidence of urticaria and/or angioedema events following mRNA vaccines for COVID-19? (01:28)    
3. How severe were these events and how were they treated? (02:16)
4. What was the conclusion of the investigators regarding the suitability of future vaccine doses in patients who experienced these events? (04:00)
5. What questions remain unanswered and what future studies are planned? (05:25)

Disclosures: Sara Anvari reports grants from NIH/NIAID (R01 AI135197 and UM2 AI130836) and DBV Technologies, outside the submitted work.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Filmed in coverage of the virtual AAAAI 2022.